Buckman R, McIlhinney R A, Shepherd V, Patel S, Coombes R C, Neville A M
Lancet. 1982 Dec 25;2(8313):1428-30. doi: 10.1016/s0140-6736(82)91329-0.
The value of a monoclonal antibody, LICR-LON-Fib-75 (Fib-75), which mediates complement lysis and recognises an antigen present on all epithelial-tumour cells so far studied but not on lymphoid cells or bone-marrow stem cells, in clearing infiltrated bone marrow was assessed. Chromium-51-release and trypan-blue-exclusion assays showed that no tumour cells were viable after exposure to Fib-75 and complement except when large clumps (greater than 500 cells) were present, whereas Fib-75 had no significant effect on bone-marrow cells, as judged by colony-forming-unit and pluripotential-stem-cell assays.
评估了一种单克隆抗体LICR-LON-Fib-75（Fib-75）在清除浸润骨髓方面的价值，该抗体介导补体溶解，能识别迄今为止所研究的所有上皮肿瘤细胞上存在的一种抗原，但在淋巴细胞或骨髓干细胞上不存在。铬-51释放试验和台盼蓝排斥试验表明，除存在大细胞团（大于500个细胞）外，暴露于Fib-75和补体后没有肿瘤细胞存活，而通过集落形成单位和多能干细胞试验判断，Fib-75对骨髓细胞没有显著影响。
